Edition:
United Kingdom

Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

26.58USD
13 Dec 2017
Change (% chg)

$0.58 (+2.23%)
Prev Close
$26.00
Open
$26.11
Day's High
$26.93
Day's Low
$25.74
Volume
152,677
Avg. Vol
66,641
52-wk High
$26.93
52-wk Low
$7.14

Summary

Name Age Since Current Position

Richard Aldrich

62 2006 Chairman of the Board, Co-Founder

Roger Tung

57 2006 President, Chief Executive Officer, Co-Founder, Director

Ryan Lynch

2017 Principal Financial Officer, Principal Accounting Officer

Nancy Stuart

55 2007 Chief Operating Officer

Robert Silverman

62 2010 Senior Vice President and General Counsel

James Cassella,

2015 Senior Vice President, chief development officer

Christine Boisclair

2016 Vice President - Regulatory Affairs

Scott Weintraub

2016 Vice President - Commercial and Product Strategy

Thomas Auchincloss

52 2014 Director

Ronald Barrett

60 2007 Director

Meghan FitzGerald

46 2016 Director

Peter Hutt

82 2006 Director

Wilfred Jaeger

61 2006 Director

Christine van Heek

58 2016 Director

Wendell Wierenga

69 2014 Director

Justine Koenigsberg

2014 Vice President - Corporate Communications

Biographies

Name Description

Richard Aldrich

Mr. Richard H. Aldrich is Chairman of the Board, Co-Founder of Concert Pharmaceuticals Inc since May 2006. Mr. Aldrich is a Founder and has been Partner of Longwood Fund, a venture capital firm, since December 2010. Mr. Aldrich founded RA Capital Management LLC, a hedge fund, in 2004 and served as a Managing Member from 2004 to 2008 and as a Co-Founding Member from 2008 until 2011. Mr. Aldrich has co-founded several biotechnology companies including Sirtris Pharmaceuticals, Inc., which was acquired by GlaxoSmithKline in 2008, and Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2011. He has also held management positions at Vertex, where he was a co-founding employee, and Biogen Corporation (now Biogen Idec Inc., a biotechnology company). Mr. Aldrich co-founded and serves on the board of directors of Verastem, Inc., a public biopharmaceutical company and also serves on the boards of directors of OvaScience, Inc., a public life sciences company of which he serves as chairman of the board, and PTC Therapeutics, Inc., a public biopharmaceutical company. Mr. Aldrich received his undergraduate degree from Boston College, and an M.B.A. from the Amos Tuck School at Dartmouth College. We believe Mr. Aldrich’s broad-based experience in business, including his leadership and board experience at life science companies, and his familiarity with our business as a co-founder of our company allows him to be a key contributor to our board of directors.

Roger Tung

Dr. Roger Tung is Co-Founder, President, Director and CEO of Concert Pharmaceuticals Inc. Before thisBefore Concert, Dr. Tung was a founding scientist at Vertex, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Discovery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare provider, and The Squibb Institute for Medicinal Chemistry. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison. We believe that Dr. Tung’s detailed knowledge of our company and his 28 year career in the global pharmaceutical and biotechnology industries, including his roles at Vertex, provide a critical contribution to our board of directors.

Ryan Lynch

Nancy Stuart

Ms. Nancy Stuart is Chief Operating Officer of Concert Pharmaceuticals Inc. She has over 20 years of biotechnology and pharmaceutical industry experience. Prior to joining Concert, Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Scion Pharmaceuticals, Inc., a pharmaceutical company, Vertex and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

Robert Silverman

Dr. Robert Silverman, Ph.D. J.D. is Senior Vice President and General Counsel of Concert Pharmaceuticals Inc. He has over 20 years legal and scientific experience. Prior to joining Concert, he served in various legal related roles at Millennium Pharmaceuticals, Inc., a pharmaceutical company, Vertex and FMC Corporation, a chemical manufacturing company. Dr. Silverman received his J.D. from Rutgers-Camden Law School, a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University.

James Cassella,

Dr. James V. Cassella, Ph.D. has served as our Senior Vice President and Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received a Ph.D. in physiological psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psychology from the University of New Haven.

Christine Boisclair

Ms. Christine Boisclair is the Vice President - Regulatory Affairs of the Company. Ms. Boisclair joins Concert with more than 30 years of regulatory affairs experience in the biopharmaceutical industry across multiple therapeutic areas. Prior to joining Concert, Ms. Boisclair was Vice President, Regulatory Affairs, at Forum Pharmaceuticals. Before joining Forum Pharmaceuticals, she held management roles at several companies including Insmed, Agennix, OSI Pharmaceuticals, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair also worked in regulatory at Searle Pharmaceuticals and Glaxo in the U.K. She received a Bachelor of Science Honors Degree in Biochemistry from the University of York in the U.K.

Scott Weintraub

Mr. Scott Weintraub is the Vice President - Commercial and Product Strategy of the Company. Mr. Weintraub joins Concert with more than 17 years of commercial experience in the biopharmaceutical industry, including strategic product assessment, brand positioning, commercial life cycle management, and sales and marketing. Prior to joining Concert, he was Vice President of Product Strategy and Marketing at Forum Pharmaceuticals. He also served as Senior Director of Marketing at Sunovion Pharmaceuticals and held sales and marketing positions at AstraZeneca. He holds a B.S. in Finance and Marketing from Florida State University and an M.B.A. in Health Administration and Policy from University of Miami.

Thomas Auchincloss

Mr. Thomas G. Auchincloss is Director of the Company. effective December 9, 2014. Since October 2013, Mr. Auchincloss has served as Managing Partner at Counterpoint Trading Company, LLC, a private investment firm. From August 2007 through September 2013, Mr. Auchincloss was self-employed in private investing. From May 2005 to August 2007, Mr. Auchincloss worked as Chief Financial Officer of Metabolix, Inc., a public biomaterials company. Prior to joining Metabolix, Mr. Auchincloss served as a consultant with Metabolix from April 2002 to May 2005 providing business development, financial and strategic consulting services. From 1994 to 2001, Mr. Auchincloss served in a variety of positions at Vertex Pharmaceuticals Incorporated, most recently as vice president, finance and treasurer. Mr. Auchincloss is trustee and Treasurer of Kieve Wavus Education, Inc. a not-for-profit camp and education organization. He also serves as an advisor to Capital Formation Group Inc., a family investment firm and Acelium, a cyber-security

Ronald Barrett

Dr. Ronald W. Barrett, Ph.D. is Director of the company. Dr. Barrett has served as a member of our board of directors since December 2007. Dr. Barrett is a founder of XenoPort, Inc., a public biopharmaceutical company, and has served as its Chief Executive Officer since 2001, its Chief Scientific Officer from 1999 to 2001 and as a member of its board of directors since 1999. Prior to XenoPort he held various positions at Affymax Research Institute, a drug discovery company now owned by GlaxoSmithKline plc, and Abbott Laboratories, a healthcare company. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University. We believe that Dr. Barrett’s industry and board experience, including his experience as the chief executive officer of a publically traded biopharmaceutical company, makes him a key contributor to our board of directors.

Meghan FitzGerald

Ms. Meghan M. FitzGerald is Director of the Company. Meg FitzGerald currently serves as the Executive Vice President of Strategy and Policy at Cardinal Health, Inc. Prior to this role, she was the president of Cardinal Health Specialty Solutions, a specialty healthcare business that offers services for healthcare providers, payers, and pharmaceutical and biotech industries. Prior to joining Cardinal Health, Ms. FitzGerald was senior vice president of New Markets International Division and Business Development at Medco Health Solutions, Inc., where she was responsible for leading business development efforts in the United States and internationally. She previously held positions of increasing responsibility at Pfizer Global Pharmaceuticals, where she supported business strategies and operations, including the implementation of ten-year lifecycle plans for various pharmaceutical products such as Celebrex. Ms. FitzGerald has also held marketing positions at Merck and Sanofi-Synthelabo. She is a member of the board of directors for SeniorLink, a provider of in home care and support for elders and individuals with disabilities, and GELESIS, a privately held biotechnology company. She recently accepted an invitation to join the World Economic Forum's Global Agenda Council on Ageing. Ms. FitzGerald also serves as a member of the adjunct faculty at Columbia University in New York, teaching The Business of Healthcare . Ms. FitzGerald obtained a Doctor of Public Health (DrPH) degree at New York Medical College, focusing on health policy. She earned a master's degree in public health from Columbia University and a bachelor's degree in nursing from Fairfield University.

Peter Hutt

Mr. Peter Barton Hutt is Director of the company. He has served as a member of our board of directors since December 2006Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975 he was Chief Counsel for the Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc., BIND Therapeutics, Inc., DBV Technologies SA, Q Therapeutics, Inc. and Xoma Ltd., each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of Celera Genomics, a public biotechnology company that was acquired by Quest Diagnostics, Inc. in 2011 and Momenta Pharmaceuticals, Inc., a biotechnology company. Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School and an LL.M. from New York University School of Law. We believe Mr. Hutt’s extensive knowledge of regulatory and legal issues related to drug development and his service on numerous boards of directors allows him to be a key contributor to our board of directors.

Wilfred Jaeger

Dr. Wilfred E. Jaeger, M.D. is director of the company. Dr. Jaeger has served as a member of our board of directors since May 2006. Dr. Jaeger co-founded Three Arch Partners, a venture capital firm, in 1993 and has served as a Partner since that time. Prior to co-founding Three Arch Partners, Dr. Jaeger was a general partner at Schroder Ventures. He is also a member of the board of directors of Threshold Pharmaceuticals, Inc., a public pharmaceutical company, as well as numerous private companies. Dr. Jaeger received a B.S. in Biology from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine and an M.B.A. from Stanford University. In addition to representing one of our principal stockholders, we believe that that Dr. Jaeger’s financial and medical knowledge and experience allows him to be a key contributor to our board of directors.

Christine van Heek

Ms. Christine van Heek is Director of the company. She has served as an advisor and consultant to several companies on global commercialization, sales, marketing and business development in the biotechnology and pharmaceutical industry. From 1991 to 2003, Ms. van Heek served in various roles at Genzyme Corporation, including Corporate Officer and President, Therapeutics Division, where she was responsible for building worldwide commercialization organizations and sales and marketing management. Under her leadership, the division expanded into over 60 countries and annual revenues grew to $700 million. In addition, she has held various sales and marketing positions at Genentech, Inc. and Caremark/HHCA. Ms van Heek served on the board of directors of Affymax, Inc. from 2007-2014. Ms. van Heek currently serves on the Board of Directors for Visioneering Technologies, Inc. She holds a B.S.N. from the University of Iowa and received her M.B.A. from Lindenwood University in St. Louis.

Wendell Wierenga

Dr. Wendell Wierenga, Ph.D. is Director of the Company. Most recently, Dr. Wierenga worked as Executive Vice President, Research and Development of Santarus, Inc., a public biopharmaceutical company that was acquired by Salix Pharmaceuticals, Ltd. in January 2014. From 2007 to May 2011, Dr. Wierenga served as Executive Vice President, Research and Development of Ambit Biosciences Corporation, a biopharmaceutical company engaged in the discovery and development of small-molecule kinase inhibitors. From 2003 to 2007, he served as Executive Vice President, Research and Development of Neurocrine Biosciences, Inc., a biopharmaceutical company developing therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases. From 2000 to 2003, Dr. Wierenga served as the Chief Executive Officer of Syrrx, Inc., biotechnology company focused on small-molecule drug compounds. Prior to joining Syrrx, from 1990 to 2000, he was senior vice president of worldwide pharmaceutical sciences, technologies and development at Parke-Davis, a division of Warner Lambert Co., a pharmaceutical company that was acquired by Pfizer Inc. in 2000. Prior to Parke-Davis, Dr. Wierenga worked at Upjohn Co., later Pharmacia & Upjohn, Inc., a pharmaceutical and biotechnology company, for 16 years in various positions, most recently as executive director of discovery research. Pfizer acquired Pharmacia & Upjohn, then named Pharmacia Corp., in 2002. Dr. Wierenga received a B.S. from Hope College and a Ph.D. in chemistry from Stanford University. Dr. Wierenga is a member of the boards of directors of Anacor Pharmaceuticals, Inc., Apricus Biosciences, Inc., Cytokinetics, Incorporated, Ocera Therapeutics, Inc. and XenoPort, Inc., which are publicly traded biopharmaceutical companies. During the last five years, Dr. Wierenga also served as a member of the boards of directors of Onyx Pharmaceuticals, Inc., a public biopharmaceutical company that was acquired by Amgen in 2013. We believe that Dr. Wierenga’s extensive experience in biopharmace

Justine Koenigsberg